Neuroendocrine tumors of the small intestine and the appendix - Management guidelines (recommended by the Polish Network of Neuroendocrine Tumors);Guzy neuroendokrynne jelita cienkiego i wyrostka robaczkowego (zasady postȩpowania rekomendowane przez Polska̧ Sieć Guzów Neuroendokrynnych)

Endokrynologia Polska

Volumn 59, Issue 1, 2008, Pages 87-96

  Bolanowski, Marek ^a,e   Jarza̧b, Barbara ^b   Handkiewicz Junak, Daria ^b   Jeziorski, Arkadiusz ^c   Kos Kudła, Beata ^d   Zajȩcki, Wojciech ^d   Bar Andziak, Ewa ^f   Ćwikła, Jarosław ^g   De Herder, Wouter ^h   Dzielicki, Józef ⁱ   Falconi, Massimo ^j   Foltyn, Wanda ^k   Gaciong, Zbigniew ^l   Hubalewska Dydejczyk, Alicja ^m   Kowalska, Aldona ⁿ   Królicki, Leszek ^o   Krzyzanowska Świniarska, Barbara ^p   Kryszałowicz, Bozena ^q   Kvols, Larry ^r   Nasierowska Guttmejer, Anna ^s   O'Toole, Dermot ^t   Kunikowska, Jolanta ^o   Lampe, Paweł ^d   Matyja, Violetta ^k   Mełeń Mucha, Gabriela ^c   Milewicz, Andrzej ^u   Nowak, Andrzej ^d   Nowakowska Duława, Ewa ^d   Omyła Staszewska, Joanna ^v   Paja̧k, Jacek ^d   Rudzki, Sławomir ^w   Rydzewska, Grazyna ^x   Sowiński, Jerzy ^y   Starzyńska, Teresa ^z   Strzelczyk, Janusz ^k   Sworczak, Krzysztof ^aa   Syrenicz, Anhelli ^ab   Szawłowski, Andrzej ^s   Tomaszewska, Romana A ^m   Waśko Czopnik, Dorota ^e   Wroński, Marek ^ac   Zemczak, Anna ^k   Zgliczyński, Wojciech ^ad   more..

^a Katedra i Klinika Endokrynologii   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ Katedra I Klinika Chirurgii Wad Rozwojowych Dzieci I Traumatologii lAM   (Poland)

^j UNIVERSITY OF VERONA   (Italy)

^k Klinika Endokrynologii   (Poland)

^l Katedra I Klinika Chorob Wewnetrznych Nadcisnienia Tetniczego I Angiologii ^*  (Poland)

^m JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

ⁿ Dzia Endokrynologii CO   (Poland)

^o Zak ad Medycyny Nuklearnej SP CSK   (Poland)

^p POMERANIAN MEDICAL UNIVERSITY   (Poland)

^q Leczenia Nieswoistych Chorob Zapalnych Jelit   (Poland)

^r UNIVERSITY OF SOUTH FLORIDA   (United States)

^s INSTITUTE OF ONCOLOGY   (Poland)

^t ST JAMES S HOSPITAL   (Ireland)

^u Klinika Endokrynologii   (Poland)

^v Klinika Onkologii   (Poland)

^w Medical University of Lublin I Katedra i Klinika Chirurgii Ogolnej i Transplantacyjnej   (Poland)

^x Klinika Chorób Wewn trznych I Gastroenterologii Centralnego Szpitala Klinicznego   (Poland)

^y POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^z Katedra Gastroenterologii AM   (Poland)

^aa MEDICAL UNIVERSITY OF GDANSK   (Poland)

^ab Nadci nienia Tetniczego i Chorób Przemiany Materii Pomorskiej AM w Szczecinie   (Poland)

^ac WIM   (Poland)

^ad MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

more..

Author keywords

Appendix; Carcinoid; Diagnostics; Neuroendocrine tumors; Small intestine; Therapy

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; SOMATOSTATIN DERIVATIVE;

APPENDIX TUMOR; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CAPSULE ENDOSCOPY; CARCINOID SYNDROME; COLONOSCOPY; ECHOGRAPHY; ENDOSCOPIC SURGERY; HISTOPATHOLOGY; HUMAN; ILEUM; LABORATORY DIAGNOSIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATIENT CARE; POLAND; PRACTICE GUIDELINE; REVIEW; SMALL INTESTINE TUMOR; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; CLINICAL COMPETENCE; COMBINED MODALITY THERAPY; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PHYSICAL EXAMINATION; POLAND; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 42249099996     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
2. Plöckinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology 2004; 80 (supl. 1): 35-38.
3. Bolanowski M, Kos-Kudła B. Możliwości rozpoznawania i leczenia guzów neuroendokrynnych przewodu pokarmowego. Post Hig Med Dośw (online) 2005; 59: 48-55.
4. Ramage JK, Davies AHG, Ardill J i wsp. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54: 1-16.
5. Modlin IM, Kidd M, Latich I i wsp. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751.
6. Burke AP, Thomas RM, Elasyed AM i wsp. Carcinoid of the jejunum and ileum: an immunohistochemical and clinicopathological study of 167 cases. Cancer 1997; 79: 1086-1093.
7. Strodel WE, Talpos G, Eckhauser F i wsp. Surgical therapy for small bowel carcinoid tumors. Arch Surg 1983; 118: 391-397.
8. Monson JP. The epidemiology of endocrine tumours. Endocr Relat Cancer 2000; 7: 29-36.
9. Godwin JD. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36: 560-569.
10. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
11. Modlin IM, Manish C, Champaneria BS. A three-decade analysis of 3911 small intestinal neuroendocrine tumors. The rapid pace of no progress. Am J Gastroenterol 2007; 102: 1-10.
12. Plöckinger U, Rindi G, Arnold R i wsp. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 2004; 80: 394-424.
13. Moertel CG, Sauer W, Dockerty M. Life history of carcinoid tumor of the small intestine. Cancer 1961; 14: 901-912.
14. Vinik AI, Thompson N, Eckhauser F i wsp. Clinical features of carcinoid syndrome and the use somatostatin analogue in its management. Acta Oncol 1989; 28: 389-402.
15. Comaru-Schally AM, Schally AV. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs. Int J Oncol 2005; 26: 301-309.
16. Soga J. Carcinoids of the small intestine: a statistical evaluation of 1102 cases collected from the literature. J Exp Clin Cancer Res 1997; 16: 353-363.
17. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813-829.
18. Nehar D, Lombard-Bohas C, Olivieri S i wsp. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol 2004; 60: 644-652.
19. Kos-Kudła B, Zemczak A. Współczesne metody rozpoznawania i leczenia guzów neuroendokrynnych układu pokarmowego. Endokrynol Pol 2006; 57: 172-184.
20. Lim TK, Hayat SA, Gaze D i wsp. Independent value of echocardiography and N-terminal pro-natriuretic peptide for the prediction of major outcomes in patients with suspected heart failure. Am J Cardiol 2007; 100: 870-875.
21. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. WHO international histological classification of tumours. Wyd. 2. Springer, Berlin 2000.
22. Rindi G, Klöppel G, Alhman H i wsp. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449 (4): 395-401.
23. van Tuyl SA, van Noorden JT, Timmer R i wsp. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 2006; 64: 66-72.
24. Shi W, Johnston CF, Buchanan KD i wsp. Localization of neuroendocrine tumours with (111In) DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 1998; 91: 295-301.
25. Krenning EP, Kwekkeboom DJ, Oei HY i wsp. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann NY Acad Sci 1994; 15: 416-424.
26. Kwekkeboom DJ, Teunissen JJ, Bakker WH i wsp. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
27. Makridis C, Oberg K, Juhlin C i wsp. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990; 14: 377-383.
28. Moertel CG, Sauer WG, Dockerty MB i wsp. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901-912.
29. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995; 19: 76-82.
30. Frilling A, Rogiers X, Malagó M i wsp. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 1998; 383: 62-70.
31. Andrews JC, Walker SC, Ackermann RJ i wsp. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med 1994; 35: 1637-1644.
32. Bilchik AJ, Wood TF, Allegra D i wsp. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasm. Arch Surg 2000; 135: 657-664.
33. Cha C, Lee FT, Rikkers LF i wsp. Rationale for the combination of cryoablation with surgical resection of hepatic tumors. Gastrointest Surg 2001; 5: 206-213.
34. Chung MH, Pisegna J, Spirt M i wsp. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130: 954-962.
35. Dousset B, Saint-Marc O, Pitre J i wsp. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20: 908-915.
36. Moertel CG, Weiland LH, Nagorney DM i wsp. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317: 1699-1701.
37. Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg 2003; 90: 1317-1322.
38. Söreide JA, van Heerden JA, Thompson GB i wsp. Gastrointestinal carcinoid tumors: Long-term prognosis for surgically treated patients. World J Surg 2000; 24: 1431-1436.
39. Wängberg B, Westberg G, Tylén U i wsp. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996; 20: 892-899.
40. Garland J, Buscombe JR, Bouvier C i wsp. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003; 17: 437-444.
41. Öberg K, Kvols L, Caplin M i wsp. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973.
42. Welin SV, Tiensuu Janson E, Sundin A i wsp. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004; 151: 107-112.
43. Kaltsas G, Mukherjee JJ, Plowman PN i wsp. The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clin Endocrinol 2001; 55: 575-587.
44. Weingarten TN, Abel MD, Connolly HM i wsp. Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases. Anesth Analg 2007; 105: 1192-1199.
45. Bernheim AM, Connolly HM, Hobday TJ i wsp. Carcinoid heart disease. Prog Cardiovasc Dis 2007; 49: 439-451.
46. Müller JE, Pellikka PA, Bernheim AM i wsp. Prognosis of carcinoid heart disease: Analysis of 200 cases over two decades. Circulation 2005; 112: 3320-3327.
47. Paganelli G, Bodei L, Handkiewicz Junak D i wsp. 90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66: 393-398.
48. Buscombe JR, Cwikla JB, Caplin ME i wsp. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 2005; 26: 969-976.